INCB123667
INCB123667 is an experimental small-molecule drug from Incyte in phase 3 trials for ovarian cancer, with its target not yet stated publicly.
Overview
INCB123667 is a small-molecule drug developed by Incyte. Its molecular target is not stated in the ClinicalTrials.gov intervention record, and OnCo has not confirmed one from the sponsor's pipeline page. It is the investigational product in 2 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including the phase 3 study NCT07214779 (Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression), in ovarian cancer. The largest, NCT07214779, plans to enrol 466 participants with primary completion expected 2028-11-15. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.
- AmivantamabApproved
- CamizestrantApproved
- Comprehensive genomic profilingStandard of care
- Liquid biopsy (ctDNA)Standard of care
- LorlatinibApproved
- MRD / molecular residual disease testingEstablished
- ADC payload neutralisersPhase 1
- BGB-16673Phase 3
- Bispecific ADCPhase 3
- BRUIN CLL-321Positive
- CaDAnCe-304Recruiting
- CIRCULATE-Japan (GALAXY / VEGA / ALTAIR)Active
- A clone report from blood at every treatment cycle
- A fast route to the matched drug when it is licensed for another cancer
- A multi-cancer platform trial of adaptive (dose-holiday) therapy
- A national rapid research autopsy network for end-stage cancer
- A standard evolvability score for every tumour
- A standing platform trial that assigns treatment by how the tumour escaped
Background: ADC sequencing, Antigen escape (antigen loss, lineage switch), BCG-unresponsive, Castration-resistant prostate cancer (CRPC), Circulating tumour DNA (ctDNA). Also on OnCo: Resistance atlas · Lines of therapy.
Trials
topTrials recruiting now
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Landmark trials
Latest papers
topQuery for this drug: (TITLE:"INCB123667" OR ABSTRACT:"INCB123667") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about INCB123667, not a curated reading list.
Similar pages
not linked directly; found by shared links- TreatmentINCA33890
Shares Incyte and the tags pipeline, ctgov-ingest.
- TreatmentINCB161734
Shares Incyte and the tags pipeline, ctgov-ingest.
- TreatmentIMP4927
Shares Ovarian cancer and the tags pipeline, ctgov-ingest.
- TreatmentOregovomab
Shares Ovarian cancer and the tags pipeline, ctgov-ingest.
- TreatmentPalacaparib
Shares Ovarian cancer and the tags pipeline, ctgov-ingest.
- TreatmentAZD5335
Shares Ovarian cancer and the tags pipeline, ctgov-ingest.
- TreatmentSHR-A1921
Shares Ovarian cancer and the tags pipeline, ctgov-ingest.
- TreatmentSofetabart Mipitecan
Shares Ovarian cancer and the tags pipeline, ctgov-ingest.